02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
07:00 , Jun 19, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Loss of olfaction as an early symptom of cerebral malaria Mouse studies suggest loss of olfaction could be an early indicator of cerebral malaria infection. In...
07:00 , Jun 25, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) CC chemokine receptor 7 (CCR7); chemokine CC motif ligand 19 (CCL19); Notch homolog 1 translocation-associated (NOTCH1) Studies in mice suggest that...
07:00 , Aug 7, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Inflammation Chronic inflammatory diseases Twist homolog 1 (TWIST1) Studies in human primary cell culture and mice suggest that antagonizing TWIST1 on...
07:00 , May 15, 2008 |  BC Innovations  |  Targets & Mechanisms

Tied to the Mast

Long-lasting, nontoxic adjuvants that enhance the often weak or insufficient immune response from nasal vaccines have been hard to find. 1 A paper in Nature Medicine now suggests that small molecule mast cell activators might...
08:00 , Mar 5, 2001 |  BioCentury  |  Tools & Techniques

Vertex: Stopping metastasis

The human chemokine receptor CXCR4 has been known since the mid-1990s as a co-factor for the entry of HIV into cells. New findings reported last week by DNAX Research Institute implicate CXCR4 and another chemokine...